Dr. Pieczonka on initial efficacy and safety data for sabizabulin (VERU-111) in mCRPC

Christopher Pieczonka, MD, director of clinical research, Crouse Health, discusses phase 2 data for the novel oral cytoskeletal disruptor sabizabulin (VERU-111) in metastatic castration-resistant prostate cancer (mCRPC) presented during the 2021 ASCO Annual Meeting (J Clin Oncol 39, 2021 [suppl 15; abstr 5056]. doi:10.1200/JCO.2021.39.15_suppl.5056). He also discusses toxicity differences between VERU-111 and docetaxel.

According to Pieczonka, additional phase 2 data for VERU-111 will be shared in September at the upcoming 2021 ESMO Annual Meeting. A phase 3 trial (NCT04844749) of VERU-111 in mCRPC has already been launched.